AU729420B2 - Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia - Google Patents

Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia Download PDF

Info

Publication number
AU729420B2
AU729420B2 AU47906/97A AU4790697A AU729420B2 AU 729420 B2 AU729420 B2 AU 729420B2 AU 47906/97 A AU47906/97 A AU 47906/97A AU 4790697 A AU4790697 A AU 4790697A AU 729420 B2 AU729420 B2 AU 729420B2
Authority
AU
Australia
Prior art keywords
vegf
blood vessel
agent
nucleic acid
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU47906/97A
Other languages
English (en)
Other versions
AU4790697A (en
Inventor
Stephen George Edward Barker
John Francis Martin
Seppo Yla-Herttuala
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ark Therapeutics Ltd
Original Assignee
Eurogene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9622852.3A external-priority patent/GB9622852D0/en
Priority claimed from GBGB9709494.0A external-priority patent/GB9709494D0/en
Priority claimed from GBGB9717791.9A external-priority patent/GB9717791D0/en
Application filed by Eurogene Ltd filed Critical Eurogene Ltd
Publication of AU4790697A publication Critical patent/AU4790697A/en
Application granted granted Critical
Publication of AU729420B2 publication Critical patent/AU729420B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
    • C12Y114/13039—Nitric-oxide synthase (NADPH dependent) (1.14.13.39)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • External Artificial Organs (AREA)
AU47906/97A 1996-11-01 1997-11-03 Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia Ceased AU729420B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9622852.3A GB9622852D0 (en) 1996-11-01 1996-11-01 Treatment of intimal hyperplasma
GB9622852 1996-11-01
GB9709494 1997-05-09
GBGB9709494.0A GB9709494D0 (en) 1997-05-09 1997-05-09 Delivery device and method
GB9717791 1997-08-21
GBGB9717791.9A GB9717791D0 (en) 1997-08-21 1997-08-21 Treatment of intimal hyperplasia
PCT/GB1997/003015 WO1998020027A2 (en) 1996-11-01 1997-11-03 Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device

Publications (2)

Publication Number Publication Date
AU4790697A AU4790697A (en) 1998-05-29
AU729420B2 true AU729420B2 (en) 2001-02-01

Family

ID=27268562

Family Applications (1)

Application Number Title Priority Date Filing Date
AU47906/97A Ceased AU729420B2 (en) 1996-11-01 1997-11-03 Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia

Country Status (14)

Country Link
US (1) US7320679B2 (enExample)
EP (2) EP1488761A1 (enExample)
JP (3) JP2001503755A (enExample)
KR (1) KR100695590B1 (enExample)
AT (1) ATE287271T1 (enExample)
AU (1) AU729420B2 (enExample)
CA (1) CA2270286C (enExample)
DE (1) DE69732304T2 (enExample)
ES (1) ES2235227T3 (enExample)
HU (1) HU223957B1 (enExample)
NO (1) NO326303B1 (enExample)
PL (1) PL189744B1 (enExample)
PT (1) PT941116E (enExample)
WO (1) WO1998020027A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US20080305999A1 (en) * 1996-11-01 2008-12-11 John Francis Martin Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia
WO1999017798A1 (en) * 1997-10-02 1999-04-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
GB9809082D0 (en) 1998-04-28 1998-06-24 Eurogene Limited Delivery device
ES2216630T3 (es) * 1998-09-09 2004-10-16 Scios Inc Metodos de tratar la hipertension dependiente de la sal.
US6596699B2 (en) 1998-09-22 2003-07-22 Biosurface Engineering Technologies, Inc. Nucleic acid coating compositions and methods
US6958147B1 (en) 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
FR2792531B1 (fr) * 1999-04-26 2003-01-31 Aventis Pharma Sa Utilisation d'adenovirus recombinant defectif comprenant un acide nucleique codant pour un facteur angiogenique pour le traitement de l'hypertension arterielle pulmonaire
JP2002543097A (ja) * 1999-04-26 2002-12-17 アバンテイス・フアルマ・エス・アー 肺動脈高血圧を治療するための血管新生促進因子をコードする核酸を含む組換え欠陥アデノウイルスの使用
IL148826A0 (en) * 1999-09-23 2002-09-12 An Go Gen Inc Cell-based gene therapy for the pulmonary system
WO2001032695A2 (en) * 1999-11-02 2001-05-10 Genentech, Inc. MODULATION OF eNOS ACTIVITY AND THERAPEUTIC USES THEREOF
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
SE0000285D0 (sv) * 1999-12-07 2000-01-31 Mika Lahtinen Medical implant
AU2001239884B2 (en) 2000-02-25 2006-08-10 Vegenics Limited Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins and screening methods for modulators
GB0012997D0 (en) * 2000-05-26 2000-07-19 Eurogene Limited Gene delivery
WO2002096469A2 (en) * 2001-05-29 2002-12-05 Ark Therapeutics Ltd. Gene delivery via a baculovirus vector
EP2572674A3 (en) * 2001-07-06 2013-08-07 Syntach AG Implantable blood pressure regulator device
SE0102578L (sv) * 2001-07-20 2003-01-21 Oeyvind Reitan Förändring av en stents egenskaper för att förhindra restenos
AU2003273391A1 (en) * 2003-06-18 2005-01-04 Georg-August-Universitat Gottingen Use of a vegf receptor gene or gene product
GB0515140D0 (en) * 2005-07-22 2005-08-31 Ark Therapeutics Ltd Therapeutic device
WO2007022287A2 (en) 2005-08-15 2007-02-22 Vegenics Limited Modified vegf and pdgf with improved angiogenic properties
ATE476986T1 (de) * 2006-01-18 2010-08-15 Gen Hospital Corp Verfahren zur steigerung der lymphatischen funktion
US8721711B2 (en) 2007-06-20 2014-05-13 Oregon Health & Science University Graft having microporous membrane for uniform fluid infusion
US8808255B2 (en) 2007-12-14 2014-08-19 Oregon Health & Science University Drug delivery cuff
DE102008002396A1 (de) 2008-06-12 2009-12-17 Biotronik Vi Patent Ag Implantierbares Wirkstoffreservoir und Vorrichtung mit einem implantierbaren Wirkstoffreservoir
PT2814513T (pt) * 2012-02-14 2018-03-02 Univ California Entrega sistémica e expressão regulada de genes parácrinos para doenças cardiovasculares e outras doenças
WO2013135266A1 (en) 2012-03-12 2013-09-19 Gemvax As Treatment of non-small cell lung carcinoma by active immunotherapy
IN2015DN00934A (enExample) 2012-08-01 2015-06-12 United Therapeutics Corp
AU2014205557B2 (en) 2013-01-09 2017-08-10 United Therapeutics Corporation Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
US11571444B2 (en) 2016-10-24 2023-02-07 United Therapeutics Corporation Enhancement of MSC immunomodulatory properties by treprostinil
WO2020204601A1 (ko) * 2019-04-05 2020-10-08 한국세라믹기술원 Csq-태그를 이용한 단백질의 발현 및 정제 방법
IT201900012537A1 (it) * 2019-07-22 2021-01-22 Milano Politecnico Dispositivo di condizionamento per condizionare un tratto esposto di un vaso sanguigno e metodo

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023668A1 (en) * 1993-04-14 1994-10-27 Emory University A device for local drug delivery and methods for using the same
WO1994028721A1 (en) * 1993-06-11 1994-12-22 The Board Of Trustees Of The Leland Stanford Junior University Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797485A (en) * 1971-03-26 1974-03-19 Alza Corp Novel drug delivery device for administering drug into blood circulation in blood vessel
JPS56122317A (en) * 1980-02-29 1981-09-25 Koken:Kk Drug transporting material and its preparation
US5201728A (en) * 1991-05-03 1993-04-13 Giampapa Vincent C Subcutaneous implantable multiple-agent delivery system
US5326568A (en) * 1991-05-03 1994-07-05 Giampapa Vincent C Method of tissue-specific delivery
US5653744A (en) * 1995-04-27 1997-08-05 Khouri Biomedical Research, Inc. Device and method for vascular anastomosis
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023668A1 (en) * 1993-04-14 1994-10-27 Emory University A device for local drug delivery and methods for using the same
WO1994028721A1 (en) * 1993-06-11 1994-12-22 The Board Of Trustees Of The Leland Stanford Junior University Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CIRCULATION VOL. 94, NO. 8 ABSTRACT 3720 *

Also Published As

Publication number Publication date
DE69732304T2 (de) 2005-06-02
HUP9902867A2 (hu) 1999-12-28
KR100695590B1 (ko) 2007-03-14
US7320679B2 (en) 2008-01-22
HUP9902867A3 (en) 2001-12-28
WO1998020027A2 (en) 1998-05-14
KR20000052999A (ko) 2000-08-25
NO992106D0 (no) 1999-04-30
DE69732304D1 (de) 2005-02-24
NO326303B1 (no) 2008-11-03
JP2012031196A (ja) 2012-02-16
NO992106L (no) 1999-06-30
PL333272A1 (en) 1999-11-22
AU4790697A (en) 1998-05-29
CA2270286A1 (en) 1998-05-14
EP0941116A2 (en) 1999-09-15
US20030225020A1 (en) 2003-12-04
JP4783797B2 (ja) 2011-09-28
ES2235227T3 (es) 2005-07-01
JP2008155036A (ja) 2008-07-10
WO1998020027A3 (en) 1998-10-08
ATE287271T1 (de) 2005-02-15
CA2270286C (en) 2009-03-03
HU223957B1 (hu) 2005-03-29
EP0941116B1 (en) 2005-01-19
JP2001503755A (ja) 2001-03-21
EP1488761A1 (en) 2004-12-22
PL189744B1 (pl) 2005-09-30
HK1108845A1 (zh) 2008-05-23
PT941116E (pt) 2005-05-31

Similar Documents

Publication Publication Date Title
US7320679B2 (en) Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia
JP5231587B2 (ja) Ｖｅｇｆ−ｃまたはｖｅｇｆ−ｄ遺伝子またはタンパク質を用いた再狭窄の予防
US8455453B2 (en) Use of VEGF-D gene to prevent restenosis
US8088160B2 (en) Drug-eluting intravascular prostheses and methods of use
US20070287682A1 (en) Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US20120308522A1 (en) Therapeutic Use of Growth Factor, and Delivery Device, Especially for the Treatment of Intimal Hyperplasia
EP0591408A1 (en) Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
EP1073427B1 (en) Periadventitial delivery device
HK1108845B (en) Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device
MXPA99004088A (en) Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia
US20020034505A1 (en) Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US20090214496A1 (en) Bmx/etk tyrosine kinase gene therapy materials and methods
Cable et al. Gene therapy for vein graft disease
US20030039694A1 (en) Periadventitial delivery device
CN1981887A (zh) 生长因子的治疗用途和特别用于内膜增生治疗的输送装置
MXPA00010167A (es) Dispositivo para suministro periadventicio

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)